Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024
Cooley M&A
JANUARY 23, 2024
Strained access to public markets and funding The IPO market remained relatively inactive in 2023, leading many life sciences companies looking to raise funds to turn to other exit strategies. Moving into Q2 of 2023, roughly 29% of US public biotech companies traded below their cash value. billion.
52 
Let's personalize your content